Loan Agreement, Trading Update and Directorate Changes
The Board of Proteome Sciences is pleased to provide a trading update and announce that it has entered into new loan agreements with Vulpes Investment Management Private Limited (“Vulpes”) and Christopher Pearce (together the “Lenders”), for a total of £1 million (the “Loan Facility”), as well as an update on Board changes.
Interim results for the six months ended 30 June 2024 and Directorate Change
Proteome Sciences announces its unaudited interim results for the six months ended 30 June 2024 (“H1 2024”).
Result of Annual General Meeting (AGM)
The directors of Proteome Sciences are pleased to announce that at the Company's AGM, held at 12.00 noon today, all resolutions were duly passed.
Substantial contract for Proteome Sciences
Proteome Sciences (AIM:PRM), is pleased to announce that the Company has secured a contract win from a US biopharmaceutical company using the Company’s mass spectrometry services for the analysis of samples for an on-going clinical trial.
Final results for the year ended 31 December 2023
The Company is pleased to announce its audited results for the year ended 31 December 2023.
Completion of new facility in San Diego
Proteome Sciences is pleased to announce the completion of installation and setup of equipment in its new US laboratory in San Diego, California. and is therefore now fully operational.
Trading update for the year 2023
The Company announces a trading update to its shareholders.
Launch of Commercial Single Cell Proteomics Services
Proteome Sciences plc is pleased to announce the launch of SysQuant® SCP, the commercial service for single cell proteomics using the power of its TMTpro™ isobaric labelling reagents.